Eupraxia Pharmaceuticals (EPRX) Corporate presentation summary

Growth outlook and financial position

• Poised for significant growth in 2026 with compelling clinical data from the RESOLVE trial in Eosinophilic Esophagitis (EoE).

• Over $130M in cash and short-term assets, supporting operations into H2 2028.

• Quarterly readouts of Phase 1b/2a data and interim Phase 2b trial data expected in Q4 2026.

• Initiation of a clinical trial in an additional indication planned for H2 2026.

• Market capitalization of $442 million as of August 2026.

Product and technology highlights

• EP-104GI targets EoE, a disease affecting over one million people in the US by 2030.

• Diffusphere™ platform enables targeted, controlled drug delivery with annual injection potential.

• Clinical data shows symptom and histologic improvement, tolerability, and durability.

• Active ingredient fluticasone propionate has a known mechanism of action and established PK profile.

• Five patent families granted globally, with expiry dates into the mid-2040s.

Clinical development and results

• RESOLVE trial is a multicenter, open-label, dose-escalation and optimization study for EP-104GI.

• Stable drug release observed out to 12 months with low systemic exposure.

• High rates of clinical remission and symptom improvement sustained over 52 weeks.

• Dose-dependent improvements in tissue health and histologic remission.

• Well-tolerated with no serious drug-related adverse events or significant changes in glucose/cortisol.